Literature DB >> 30304523

Expression Analysis of Long Non-Coding RNA HAR1A and HAR1B in HBV-Induced Hepatocullular Carcinoma in Chinese Patients.

Zhenjing Shi1, Ya Luo1, Minghui Zhu2, Yu Zhou3, Bingru Zheng1, Daoyi Wu4, Shuting Wang5, Xiangbang Xie1, Heping Lin6, Xixiang Yu7.   

Abstract

OBJECTIVE: To determine the clinical relevance of long noncoding RNA (lncRNA) HAR1A and HAR1B expression in hepatocellular carcinoma (HCC).
METHODS: In this study, we enrolled 50 cases of chronic hepatitis B (CHB) without cirrhosis, 50 cases of CHB and liver cirrhosis (LC), and 100 cases of HBV and HCC. The expression profiles of lncRNA HAR1A and HAR1B were analyzed using reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
RESULTS: The expression levels of HAR1A and HAR1B were significantly lower in the HCC group, compared with the CHB and LC groups (P <.01). HAR1A and HAR1B were negatively associated with histologic grade and TNM (tumor/nodes/metastasis) stage (all P <.05). Univariable multivariable analysis showed that decreased HAR1A (HR = 0.753, P = .02) and HAR1B (HR = 0.551, P = .01) levels were independent predictors for shorter overall survival (OS) in HCC.
CONCLUSION: Decreased HAR1A and HAR1B expression in HCC indicates poor prognosis. © American Society for Clinical Pathology 2018. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 HAR1Azzm321990 ; zzm321990 HAR1Bzzm321990 ; RT-qPCR; expression; hepatocellular carcinoma; survival

Mesh：

Substances：

Year:  2019        PMID： 30304523     DOI： 10.1093/labmed/lmy055

Source DB:  PubMed          Journal:  Lab Med        ISSN： 0007-5027


  6 in total

1.  LncRNA HAR1A Suppresses the Development of Non-Small Cell Lung Cancer by Inactivating the STAT3 Pathway.

Authors:  Jianqun Ma; Kui Cao; Xiaodong Ling; Ping Zhang; Jinhong Zhu
Journal:  Cancers (Basel)       Date:  2022-06-08       Impact factor: 6.575

2.  DNMBP-AS1 Regulates NHLRC3 Expression by Sponging miR-93-5p/17-5p to Inhibit Colon Cancer Progression.

Authors:  Lijie Yang; Tiecheng Yang; Huaqiao Wang; Tingting Dou; Xiaochang Fang; Liwen Shi; Xuanfei Li; Maohui Feng
Journal:  Front Oncol       Date:  2022-04-27       Impact factor: 5.738

3.  Long Non-coding RNA Expression Profiling Identifies a Four-Long Non-coding RNA Prognostic Signature for Isocitrate Dehydrogenase Mutant Glioma.

Authors:  Yusheng Chen; Yang Guo; Hang Chen; Fengjin Ma
Journal:  Front Neurol       Date:  2020-11-20       Impact factor: 4.003

4.  lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma.

Authors:  Hideharu Yamada; Masanobu Takahashi; Munenori Watanuki; Mika Watanabe; Sakura Hiraide; Ken Saijo; Keigo Komine; Chikashi Ishioka
Journal:  Oncol Lett       Date:  2021-04-08       Impact factor: 2.967

5.  Long noncoding RNA HAR1A regulates oral cancer progression through the alpha-kinase 1, bromodomain 7, and myosin IIA axis.

Authors:  Chi-Pin Lee; Albert Min-Shan Ko; Srinivasan Nithiyanantham; Chu-Hu Lai; Ying-Chin Ko
Journal:  J Mol Med (Berl)       Date:  2021-06-07       Impact factor: 4.599

6.  Development of an Immune-Related LncRNA Prognostic Signature for Glioma.

Authors:  Yudong Cao; Hecheng Zhu; Jun Tan; Wen Yin; Quanwei Zhou; Zhaoqi Xin; Zhaoping Wu; Zhipeng Jiang; Youwei Guo; Yirui Kuang; Can Li; Ming Zhao; Xingjun Jiang; Jiahui Peng; Caiping Ren
Journal:  Front Genet       Date:  2021-06-14       Impact factor: 4.599
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.